IDEXX Laboratories Aktie

IDEXX Laboratories für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN: 888210 / ISIN: US45168D1046

<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
04.08.2025 13:14:38

IDEXX Labs Lifts FY25 Outlook Above Market After Q2 Beats Street; Stock Gains In Pre-market

(RTTNews) - IDEXX Laboratories, Inc. (IDXX), while reporting higher second-quarter results above the Street, on Monday raised its outlook for fiscal 2025 earnings and revenues, both above market estimates.

In the pre-market activity on the Nasdaq, IDEXX shares were gaining around 5 percent to trade at $562.11.

For fiscal 2026, the company now expects earnings per share of $12.40 to $12.76, representing a year-over-year growth of 16 percent to 20 percent. The company previously expected earnings per share of $11.93 to $12.43, a growth of 12 percent to 17 percent from last year.

The Wall Street analysts on average expect the company to report earnings of $12.21 per share. Analysts' estimates typically exclude special items.

The revision reflects certain one-time benefits. The updated outlook is 9 percent to 13 percent growth on a comparable basis.

Further, IDEXX updated the lower end of its full-year reported operating margin outlook, and now expects between 31.3 percent and 31.6 percent from previously expected 31.1 percent to 31.6 percent.

Annual revenue guidance range has been lifted to $4.205 billion to $4.280 billion or reported growth of 7.7 percent to 9.7 percent from last year, an increase of $90 million at midpoint. The previous outlook was $4.095 billion to $4.210 billion, or 5.0 percent - 8.0 percent year-over-year growth.

The Street expects revenues of $4.15 billion.

The Company lifted the lower end of outlook for organic revenue growth to 7 percent to 9 percent from previous view of 6 percent to 9 percent.

In the second quarter, IDEXX's net income totaled $293.99 million or $3.63 per share, compared to $203.30 million, or $2.44 per share, last year.

Adjusted earnings of $3.50 per share for the period. Analysts had expected the company to earn $3.30 per share.

The company's revenue for the period rose 10.6 percent to $1.109 billion from $1.003 billion last year. The Street was looking for revenues of $1.07 billion.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

Analysen zu IDEXX Laboratoriesmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

IDEXX Laboratories 553,40 1,43% IDEXX Laboratories